ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in Kansas City, KS

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Colorectal Cancer
Cancer
Squamous Cell Carcinoma of Head and Neck
Neoplasm Metastasis
Melanoma

Non-Small-Cell Lung Cancer trials near Kansas City, KS, USA:

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (LIVIGNO-4)

Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mort...

Enrolling
Non-Small Cell Lung Cancer
Drug: Carboplatin
Drug: Livmoniplimab

Phase 2, Phase 3

AbbVie
AbbVie

Westwood, Kansas, United States and 61 other locations

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC)....

Enrolling
Stage III Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer
Biological: IOV-4001

Phase 1, Phase 2

Iovance Biotherapeutics

Westwood, Kansas, United States and 10 other locations

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Telisotuzumab vedotin

Phase 2

AbbVie
AbbVie

Kansas City, Kansas, United States and 254 other locations

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor (ARTEMIA)

Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI...

Enrolling
Patients With Non-Small Cell Lung Cancer
Drug: OSE2101
Drug: Docetaxel

Phase 3

OSE Immunotherapeutics
OSE Immunotherapeutics

Merriam, Kansas, United States and 207 other locations

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the-...

Enrolling
Non-small Cell Lung Cancer
Drug: Nab-paclitaxel
Drug: Pembrolizumab

Phase 3

AstraZeneca
AstraZeneca

Kansas City, Missouri, United States and 327 other locations

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

alone for the treatment of locally advanced or metastatic non-small cell lung cancer. Some lung ...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Pemetrexed/Carboplatin
Drug: Pemetrexed/Cisplatin

Phase 3

AstraZeneca
AstraZeneca

Kansas City, Kansas, United States and 152 other locations

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell...

Enrolling
Non Small Cell Lung Cancer
Drug: Docetaxel
Biological: Telisotuzumab Vedotin

Phase 3

AbbVie
AbbVie

Kansas City, Missouri, United States and 322 other locations

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS ...

Enrolling
Metastatic Non-Small Cell Lung Cancer
Advanced Lung Carcinoma
Drug: Pembrolizumab
Drug: BBO-10203

Phase 1

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Kansas City, Kansas, United States and 37 other locations

Locations recently updated

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high leve...

Enrolling
Carcinoma, Non-Small-Cell Lung (NSCLC)
Carcinoma, Non-Small-Cell Lung
Drug: Pembrolizumab
Drug: Sigvotatug Vedotin

Phase 3

Pfizer
Pfizer

Kansas City, Missouri, United States and 389 other locations

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung15)

This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in t...

Enrolling
Metastatic Non-small Cell Lung Cancer
Drug: Pemetrexed
Drug: Cisplatin

Phase 3

AstraZeneca
AstraZeneca

Kansas City, Missouri, United States and 300 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems